Sucraid
Payments companies reported to CMS as associated with Sucraid. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Sucraid, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Sucraid
These are the largest totals companies reported as associated with Sucraid. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Daksesh Patel | Evanston, IL | Gastroenterology (Internal Medicine) | $308,286.08 |
| David Lo | Columbus, OH | Gastroenterology (Internal Medicine) | $79,139.74 |
| Christine Frissora | New York, NY | Gastroenterology (Internal Medicine) | $59,776.64 |
| Maryam Shambayati | Oklahoma City, OK | Pediatric Gastroenterology | $37,334.26 |
| Helena In'T Veld | Phoenix, AZ | Nurse Practitioner | $32,863.40 |
| Brooks Cash | Houston, TX | Gastroenterology (Internal Medicine) | $27,146.48 |
| Fred Fowler | Charlotte, NC | Gastroenterology (Internal Medicine) | $21,045.97 |
| Amana Nasir | Saint Louis, MO | Pediatric Gastroenterology | $14,100.44 |
| Felix Rabito | Covington, LA | Gastroenterology (Internal Medicine) | $9,895.07 |
| Julie Khlevner | New York, NY | Pediatric Gastroenterology | $9,832.88 |
Prescribed Sucraid?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.